拉米夫定治疗重度黄疸型慢性乙型肝炎临床疗效观察

目的评估拉米夫定治疗重度黄疸型慢性乙型肝炎(CHB)的短期疗效,观察血清HBV DNA水平与血清总胆红素(TBIL)水平之间的关系.方法179例重度黄疸型慢性乙型肝炎患者分为观察组101例和对照组78例.观察组给予拉米夫定100mg,每天1次口服,同时给予常规护肝治疗,治疗12周.对照组给予常规护肝治疗,治疗12周.结果观察组血清HBV DNA的下降水平明显好于对照组(P＜0.01),血清HBV DNA阴转率(＜5×102拷贝/ml)为91.1%,而对照组仅为14.1%.观察组丙氨酸转氨酶、TBIL下降水平均明显好于对照组(P值均＜0.01).线性回归分析y=85.534x-153.4,R2=0.9661(P＜0.01).结论短期应用拉米夫定治疗重度黄疸型CHB疗效明显好于常规护肝治疗,观察组血清HBV DNA水平与TBIL水平间存在相关性.

Effiects of lamivudine in treatment of chronic hepatitis B patients with severe jaundice

Objective To evaluate the short-term efficacy of lamivudine treatment for chronic hepatitis B with severe jaundice, and the relationship between HBV DNA and jaundice. Methods One hundred and seventy-nine patients with chronic hepatitis B with sever jaundice were divided into lamivudine group and control group. Patients in both groups received conventional medicine for 12 week, One group also received lamivudine concomitently for 12 weeks.Results After 12 weeks of treatment, the negativity of HBV DNA (<500 copy/ml) was 91.1% in lamivudine group, while the negativity of HBV DNA was 14.1% in control group. ALT levels in lamivudine group was lower than that in control group Serum HBV DNA levels of Lamivudine group showed a linear correlation with serum TBIL levels, y= 85.543x -153.4,R~2=0.9661(P< 0.01 ). Conclusion The short-term efficacy of lamivudine treatment for chronic hepatitis B with severe jaundice were better than conventional treatment. The serum HBV DNA levels has a linear correlation with serum TBIL levels.